X0206 3 2025-04-01 0 0001781174 Acrivon Therapeutics, Inc. ACRV 0002061876 Levy Adam D. C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 true Chief Financial Officer Common Stock 13315 D Stock Option (Right to Buy) 11.26 2033-08-15 Common Stock 43425 D Stock Option (Right to Buy) 5.7 2034-02-28 Common Stock 38500 D Stock Option (Right to Buy) 5.31 2035-02-28 Common Stock 74100 D These shares include 10,856 restricted stock units ("RSUs") from an original grant of 14,475 RSUs on August 16, 2023. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of the original 14,475 RSUs granted, twenty-five percent (25%) vested on August 1, 2024, and the remaining RSUs vest in 3 substantially equal annual installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Twenty-five percent (25%) of the shares subject to the option vested on August 1, 2024, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Twenty-five percent (25%) of the shares subject to the option vested on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Exhibit List: Exhibit 24 - Power of Attorney /s/ Adam D. Levy 2025-04-03